# Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

> **NCT05620628** · PHASE2 · RECRUITING · sponsor: **Jeeyun Lee** · enrollment: 25 (estimated)

## Conditions studied

- Stomach Cancer, Adenocarcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Savolitinib

## Key facts

- **NCT ID:** NCT05620628
- **Lead sponsor:** Jeeyun Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620628, "Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05620628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*